Evidence map›Paper›PMID 35916589›Full record

ArticleJournal of global health2022

COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?

Oluwatosin Wuraola Akande, Ehimario Uche Igumbor, Kelly Osezele Elimian, Cornelius Ehizokhai Ohonsi, Lilian Nwozor, Okanke Oden, Emmanuel Nsa Ekpenyong, Nnaemeka Ndodo, Ifeanyi F Ike, Magdalene Egede and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Oluwatosin Wuraola AkandeNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Ehimario Uche IgumborNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Kelly Osezele ElimianNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Cornelius Ehizokhai OhonsiNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Lilian NwozorNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Okanke OdenNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Emmanuel Nsa EkpenyongNigeria COVID-19 Research Coalition (NCRC), Abuja, Nigeria.
Nnaemeka NdodoNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Ifeanyi F IkeNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Magdalene EgedeNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
William NwachukwuNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Amedu M OnojaNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Jenson Gawain FofahNigeria COVID-19 Research Coalition (NCRC), Abuja, Nigeria.
Reuben Ishiaku AziNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Chinwe L OchuNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.
Ifedayo M AdetifaNigeria Centre for Disease Control (NCDC), Abuja, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesHumansNigeriaResearchVaccine EfficacyCOVID-19 Vaccines

Identifiers

PMID35916589
PMCPMC9344979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.